
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is considered a promising investment due to their investigational drug assets that target Alzheimer's disease, a disease with no cure, prevention, or means of slowing progression. IGC-AD1 has shown significant potential in preclinical studies and is currently in a Phase 2B trial for agitation in dementia from Alzheimer's disease, while the company is also working on other drugs targeting Alzheimer's disease. Additionally, the company's recent fiscal year change from March to December and reported positive interim results add to the positive outlook for this stock in the long-term.
Bears say
IGC Pharma is facing significant risks to attain their share price target, such as balance sheet and liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, and the need to gain regulatory approvals. Despite their recent positive interim results from their ongoing Phase 2 trial for IGC-AD1 as a treatment for agitation in dementia from Alzheimer's disease, the company has a long road ahead and will need additional positive data and progress to drive their stock price. With over 70% patient enrollment in their Phase 2 CALMA trial and potential billion dollars market potential, there may be high rewards for the risks, but the company's outlook remains negative for now.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares